Rituximab for Immune Hemolytic Anemia following T- and B-Cell-Depleted Hematopoietic Stem Cell Transplantation
- 1 December 2002
- journal article
- case report
- Published by S. Karger AG in Acta Haematologica
- Vol. 109 (1), 43-45
- https://doi.org/10.1159/000067271
Abstract
The treatment of immune-mediated hemolytic anemia (IHA) complicating hematopoietic stem cell transplantation (HSCT) is often unsatisfactory. We report a case of IHA which occurred after T- and B-cell depleted unrelated donor HSCT carried out for mucopolysaccharidosis type I-H (Hurler syndrome) which was successfully treated with anti-CD20+ monoclonal antibodyKeywords
This publication has 6 references indexed in Scilit:
- Treatment of childhood autoimmune haemolytic anaemia with rituximabThe Lancet, 2001
- Favourable response to therapy with the anti‐CD20 monoclonal antibody rituximab in primary chronic cold agglutinin diseaseBritish Journal of Haematology, 2001
- Immune haemolytic anaemia following T cell-depleted allogeneic bone marrow transplantation for chronic myeloid leukaemia: association with leukaemic relapse and treatment with donor lymphocyte infusionsBone Marrow Transplantation, 2001
- Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpuraBlood, 2001
- Autologous peripheral blood stem cell transplantation and anti-B-cell directed immunotherapy for refractory auto-immune haemolytic anaemia.European Journal of Pediatrics, 2001
- Anti-CD20 monoclonal antibody for the treatment of severe, immune-mediated, pure red cell aplasia and hemolytic anemiaBlood, 2001